Ankyra has begun trials of its lead candidate, ANK-101, an anchored IL-12 drug conjugate initially engineered in the Wittrup and former Irvine Labs with support from KI trainee fellowships and the Marble Center for Cancer Nanomedicine. Given in combination with checkpoint blockade immunotherapy, ANK-101 will be evaluated for treatment of patients with lung cancer.